Table 1. A sample of the reformatted table.
| ClinicalTrials.gov ID | Serious adverse event | Number of patients with SAE in control arm | Number of patients in control arm | Control arm | Number of patients with SAE in drug arm | Number of patients in drug arm | Drug arm |
|---|---|---|---|---|---|---|---|
| NCT00089791 | Bladder cancer | 3 | 3,876 | Placebo | 4 | 3,886 | Denosumab 60 mg Q6M |
| NCT00089791 | Breast cancer | 25 | 3,876 | Placebo | 34 | 3,886 | Denosumab 60 mg Q6M |
| NCT00089791 | Colon cancer | 8 | 3,876 | Placebo | 11 | 3,886 | Denosumab 60 mg Q6M |
| NCT00120289 | Lung neoplasm malignant | 14 | 1,696 | Placebo + Simvastatin | 8 | 1,718 | ERN + Simvastatin |
| NCT00120289 | Malignant melanoma | 4 | 1,696 | Placebo + Simvastatin | 1 | 1,718 | ERN + Simvastatin |
| NCT00120289 | Non-small cell lung cancer | 4 | 1,696 | Placebo + Simvastatin | 0.3 | 1,718 | ERN + Simvastatin |
| NCT00143507 | Colon cancer | 7 | 5,430 | Placebo | 5 | 5,477 | Ivabradine |
| NCT00143507 | Rectal cancer | 6 | 5,430 | Placebo | 3 | 5,477 | Ivabradine |